(a TNFi receptor biologic) and secukinumab (an IL-17i biologic) are not When the evidence was low or very-low quality, the panel could not be confident in the judgment of net benefit-thus the conditional recommendation. Often, low-or very-low-quality evidence came from indirect evidence, for instance from rheumatoid arthritis http://onlinelibrary.wiley.com/doi/10.1002/art.40726/ abstract We recognize that these recommendations do not account for the full complexity of PsA or the full range of